贝林妥欧单抗治疗儿童复发/难治性B细胞急性淋巴细胞白血病:RIALTO扩展可及性研究最终分析
RIALTO是一项开放标签、单臂扩展可及性研究,评估贝林妥欧单抗治疗儿童复发/难治性B细胞前体急性淋巴细胞白血病的安全性和疗效。110例患者接受最多5个周期持续输注,3-4级细胞因子释放综合征发生2例(1.8%),3-4级神经系统事件4例(3.6%),无治疗相关致死性不良事件。中位总生存期14.6个月,MRD应答者总生存显著优于无应答者(HR 0.18,95%CI 0.08-0.39)。
要点
- 贝林妥欧单抗治疗儿童复发/难治性B-ALL的3-4级细胞因子释放综合征和神经系统事件发生率低。
- MRD应答者总生存显著优于MRD无应答者(HR 0.18,95%CI 0.08-0.39)。
- 2周期后达完全缓解的患者中73.5%(95%CI 61.4%-83.5%)后续接受异基因造血干细胞移植。
核心结论
- 研究结果支持贝林妥欧单抗作为儿童复发/难治性B细胞急性淋巴细胞白血病安全有效的治疗选择。
研究设计与样本
- 开放标签、单臂扩展可及性研究(RIALTO),纳入110例CD19+复发/难治性B细胞前体急性淋巴细胞白血病儿童(>28天且<18岁),接受最多5个周期贝林妥欧单抗持续输注(每周期用药4周、停药2周)。
- 主要终点为不良事件发生率,次要终点包括前2个周期内完全缓解和可测量残留病应答、无复发生存、总生存及治疗后异基因造血干细胞移植。
主要发现
- 最终数据截止(2020年1月10日)时共纳入110例患者,中位年龄8.5岁,88%基线原始细胞≥5%。
- 3-4级细胞因子释放综合征发生2例(1.8%),3-4级神经系统事件发生4例(3.6%),未记录到贝林妥欧单抗相关致死性不良事件。
- 细胞遗传学/分子学异常的存在不影响获得应答的概率。
- 中位总生存期14.6个月(95%CI 11.0-不可估计),MRD应答者总生存显著优于MRD无应答者(不可估计 vs 9.3个月;HR 0.18,95%CI 0.08-0.39)。
- 2周期后达完全缓解的患者中,73.5%(95%CI 61.4%-83.5%)接受异基因造血干细胞移植;贝林妥欧单抗治疗后接受移植者1年总生存概率高于未移植者(87% vs 29%)。
临床怎么用
- 原文结论认为贝林妥欧单抗是儿童复发/难治性B细胞急性淋巴细胞白血病安全有效的治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The safety and efficacy of blinatumomab, a CD3/CD19-directed bispecific molecule, were examined in an open-label, single-arm, expanded access study (RIALTO). Children (>28 days and <18 years) with CD19+ relapsed/refractory B-cell precursor acute lymphoblastic leukemia (R/R B-ALL) received up to 5 cycles of blinatumomab by continuous infusion (cycle: 4 weeks on/2 weeks off). The primary end point was incidence of adverse events. Secondary end points included complete response (CR) and measurable residual disease (MRD) response within the first 2 cycles and relapse-free survival (RFS), overall survival (OS), and allogeneic hematopoietic stem cell transplant (alloHSCT) after treatment. At final data cutoff (10 January 2020), 110 patients were enrolled (median age, 8.5 years; 88% had ≥5% baseline blasts). A low incidence of grade 3 or 4 cytokine release syndrome (n = 2; 1.8%) and neurologic events (n = 4; 3.6%) was reported; no blinatumomab-related fatal adverse events were recorded. The probability of response was not affected by the presence of cytogenetic/molecular abnormalities. Median OS was 14.6 months (95% confidence interval [CI]: 11.0-not estimable) and was significantly better for MRD responders vs MRD nonresponders (not estimable vs 9.3; hazard ratio, 0.18; 95% CI: 0.08-0.39). Of patients achieving CR after 2 cycles, 73.5% (95% CI: 61.4%-83.5%) proceeded to alloHSCT. One-year OS probability was higher for patients who received alloHSCT vs without alloHSCT after blinatumomab (87% vs 29%). These findings support the use of blinatumomab as a safe and efficacious treatment of pediatric R/R B-ALL. This trial was registered at www.clinicaltrials.gov as #NCT02187354.
引用
- Locatelli F, Zugmaier G, Mergen N, et al. Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. Blood Adv. 2022. PMID: 34979020. doi:10.1182/bloodadvances.2021005579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。